Axion BioSystems Acquires CytoSMART Technologies

Micro Imaging Technology Acquires Cellmyx

June 5, 2026

Healthcare Services

Micro Imaging Technology (MIT), a California-based public company, announced its acquisition of Cellmyx to expand its regenerative medicine and medical aesthetics portfolio. The deal combines Cellmyx’s autologous adipose grafting and transfer technologies (IntelliFat BOD) with MIT’s recently acquired SaltMed/SaltFacial to broaden manufacturing capabilities and product offerings for orthopedic, plastic, and cosmetic surgery use cases.

BioIVT Acquires BeCytes Biotechnologies

November 4, 2025

Biotechnology

BioIVT has acquired BeCytes Biotechnologies, a Barcelona-based provider of ethically sourced human tissues and primary cell isolation services. The deal expands BioIVT's European footprint and strengthens its capabilities for New Approach Methodologies (NAMs) and ADME research; BeCytes will continue to operate from Barcelona and financial terms were not disclosed.

Axonius Acquires Cynerio

July 30, 2025

Cybersecurity

Axonius has acquired Cynerio, a specialist in medical-device and healthcare IoT security, to accelerate the company's expansion into the healthcare market. Deal terms were reported at about $180 million (potentially rising to $250 million on milestones), while Axonius' announcement described the transaction as "more than $100 million" in a cash-and-stock deal.

Summa Equity Acquires Majority Stake in Axion BioSystems

July 15, 2021

Medical Devices

Summa Equity Fund II has acquired a majority stake in Axion BioSystems, a US life science tools company that develops MEA (microelectrode array) and impedance-based bioelectronic assay technologies. Summa plans to support Axion's commercial scale-up and global growth to accelerate adoption of its platforms across academia and biopharma, particularly in cell and gene therapy and drug discovery applications.

Verdesian Life Sciences Acquires Cytozyme Laboratories

April 27, 2021

Agriculture

Verdesian Life Sciences has acquired Cytozyme Laboratories, Inc.; Cascadia Capital served as exclusive financial advisor to Cytozyme. The acquisition brings together complementary biological and nutritional crop technologies to expand Verdesian's product portfolio and support sustainable yield solutions for growers.

StemBioSys Acquires Majority Stake in Cartox

January 8, 2020

Biotechnology

San Antonio-based StemBioSys acquired a majority stake in Ann Arbor startup Cartox, obtaining control with plans to purchase the remaining equity subject to milestones. The deal brings Cartox's cardiotoxicity imaging and assay capabilities together with StemBioSys's CELLvo extracellular matrix technology to accelerate commercial development of pre-clinical cardiac safety and efficacy screening solutions.